img

Global Biosimilar Insulin Glargine Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Biosimilar Insulin Glargine Market Insights, Forecast to 2034

Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours. Insulin glargine is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.
Global Biosimilar Insulin Glargine market is expected to reach to US$ 2097.9 million in 2024, with a positive growth of %, compared with US$ 2046.4 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Biosimilar Insulin Glargine industry is evaluated to reach US$ 2476 million in 2029. The CAGR will be 2.8% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Biosimilar Insulin Glargine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Biosimilar Insulin Glargine market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Eli Lilly
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Segment by Type
Pre-filled
Cartridge

Segment by Application


Hospital
Retail Pharmacy
Others

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Biosimilar Insulin Glargine plant distribution, commercial date of Biosimilar Insulin Glargine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Biosimilar Insulin Glargine introduction, etc. Biosimilar Insulin Glargine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Biosimilar Insulin Glargine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Biosimilar Insulin Glargine Product Introduction
1.2 Market by Type
1.2.1 Global Biosimilar Insulin Glargine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Pre-filled
1.2.3 Cartridge
1.3 Market by Application
1.3.1 Global Biosimilar Insulin Glargine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Biosimilar Insulin Glargine Sales Estimates and Forecasts 2018-2029
2.2 Global Biosimilar Insulin Glargine Revenue by Region
2.2.1 Global Biosimilar Insulin Glargine Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Biosimilar Insulin Glargine Revenue by Region (2018-2024)
2.2.3 Global Biosimilar Insulin Glargine Revenue by Region (2024-2029)
2.2.4 Global Biosimilar Insulin Glargine Revenue Market Share by Region (2018-2029)
2.3 Global Biosimilar Insulin Glargine Sales Estimates and Forecasts 2018-2029
2.4 Global Biosimilar Insulin Glargine Sales by Region
2.4.1 Global Biosimilar Insulin Glargine Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Biosimilar Insulin Glargine Sales by Region (2018-2024)
2.4.3 Global Biosimilar Insulin Glargine Sales by Region (2024-2029)
2.4.4 Global Biosimilar Insulin Glargine Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Biosimilar Insulin Glargine Sales by Manufacturers
3.1.1 Global Biosimilar Insulin Glargine Sales by Manufacturers (2018-2024)
3.1.2 Global Biosimilar Insulin Glargine Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Biosimilar Insulin Glargine in 2022
3.2 Global Biosimilar Insulin Glargine Revenue by Manufacturers
3.2.1 Global Biosimilar Insulin Glargine Revenue by Manufacturers (2018-2024)
3.2.2 Global Biosimilar Insulin Glargine Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Biosimilar Insulin Glargine Revenue in 2022
3.3 Global Key Players of Biosimilar Insulin Glargine, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Biosimilar Insulin Glargine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Biosimilar Insulin Glargine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Biosimilar Insulin Glargine, Product Offered and Application
3.8 Global Key Manufacturers of Biosimilar Insulin Glargine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Biosimilar Insulin Glargine Sales by Type
4.1.1 Global Biosimilar Insulin Glargine Historical Sales by Type (2018-2024)
4.1.2 Global Biosimilar Insulin Glargine Forecasted Sales by Type (2024-2029)
4.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Type (2018-2029)
4.2 Global Biosimilar Insulin Glargine Revenue by Type
4.2.1 Global Biosimilar Insulin Glargine Historical Revenue by Type (2018-2024)
4.2.2 Global Biosimilar Insulin Glargine Forecasted Revenue by Type (2024-2029)
4.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2029)
4.3 Global Biosimilar Insulin Glargine Price by Type
4.3.1 Global Biosimilar Insulin Glargine Price by Type (2018-2024)
4.3.2 Global Biosimilar Insulin Glargine Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Biosimilar Insulin Glargine Sales by Application
5.1.1 Global Biosimilar Insulin Glargine Historical Sales by Application (2018-2024)
5.1.2 Global Biosimilar Insulin Glargine Forecasted Sales by Application (2024-2029)
5.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Application (2018-2029)
5.2 Global Biosimilar Insulin Glargine Revenue by Application
5.2.1 Global Biosimilar Insulin Glargine Historical Revenue by Application (2018-2024)
5.2.2 Global Biosimilar Insulin Glargine Forecasted Revenue by Application (2024-2029)
5.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2029)
5.3 Global Biosimilar Insulin Glargine Price by Application
5.3.1 Global Biosimilar Insulin Glargine Price by Application (2018-2024)
5.3.2 Global Biosimilar Insulin Glargine Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Biosimilar Insulin Glargine Market Size by Type
6.1.1 US & Canada Biosimilar Insulin Glargine Sales by Type (2018-2029)
6.1.2 US & Canada Biosimilar Insulin Glargine Revenue by Type (2018-2029)
6.2 US & Canada Biosimilar Insulin Glargine Market Size by Application
6.2.1 US & Canada Biosimilar Insulin Glargine Sales by Application (2018-2029)
6.2.2 US & Canada Biosimilar Insulin Glargine Revenue by Application (2018-2029)
6.3 US & Canada Biosimilar Insulin Glargine Market Size by Country
6.3.1 US & Canada Biosimilar Insulin Glargine Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Biosimilar Insulin Glargine Sales by Country (2018-2029)
6.3.3 US & Canada Biosimilar Insulin Glargine Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Biosimilar Insulin Glargine Market Size by Type
7.1.1 Europe Biosimilar Insulin Glargine Sales by Type (2018-2029)
7.1.2 Europe Biosimilar Insulin Glargine Revenue by Type (2018-2029)
7.2 Europe Biosimilar Insulin Glargine Market Size by Application
7.2.1 Europe Biosimilar Insulin Glargine Sales by Application (2018-2029)
7.2.2 Europe Biosimilar Insulin Glargine Revenue by Application (2018-2029)
7.3 Europe Biosimilar Insulin Glargine Market Size by Country
7.3.1 Europe Biosimilar Insulin Glargine Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Biosimilar Insulin Glargine Sales by Country (2018-2029)
7.3.3 Europe Biosimilar Insulin Glargine Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Biosimilar Insulin Glargine Market Size
8.1.1 China Biosimilar Insulin Glargine Sales (2018-2029)
8.1.2 China Biosimilar Insulin Glargine Revenue (2018-2029)
8.2 China Biosimilar Insulin Glargine Market Size by Application
8.2.1 China Biosimilar Insulin Glargine Sales by Application (2018-2029)
8.2.2 China Biosimilar Insulin Glargine Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Biosimilar Insulin Glargine Market Size by Type
9.1.1 Asia Biosimilar Insulin Glargine Sales by Type (2018-2029)
9.1.2 Asia Biosimilar Insulin Glargine Revenue by Type (2018-2029)
9.2 Asia Biosimilar Insulin Glargine Market Size by Application
9.2.1 Asia Biosimilar Insulin Glargine Sales by Application (2018-2029)
9.2.2 Asia Biosimilar Insulin Glargine Revenue by Application (2018-2029)
9.3 Asia Biosimilar Insulin Glargine Sales by Region
9.3.1 Asia Biosimilar Insulin Glargine Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Biosimilar Insulin Glargine Revenue by Region (2018-2029)
9.3.3 Asia Biosimilar Insulin Glargine Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Biosimilar Insulin Glargine Market Size by Type
10.1.1 Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Biosimilar Insulin Glargine Market Size by Application
10.2.1 Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales by Country
10.3.1 Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Information
11.1.2 Eli Lilly Overview
11.1.3 Eli Lilly Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Eli Lilly Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Eli Lilly Recent Developments
11.2 Gan&Lee
11.2.1 Gan&Lee Company Information
11.2.2 Gan&Lee Overview
11.2.3 Gan&Lee Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Gan&Lee Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Gan&Lee Recent Developments
11.3 Tonghua Dongbao
11.3.1 Tonghua Dongbao Company Information
11.3.2 Tonghua Dongbao Overview
11.3.3 Tonghua Dongbao Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Tonghua Dongbao Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Tonghua Dongbao Recent Developments
11.4 United Laboratory
11.4.1 United Laboratory Company Information
11.4.2 United Laboratory Overview
11.4.3 United Laboratory Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 United Laboratory Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 United Laboratory Recent Developments
11.5 Geropharm
11.5.1 Geropharm Company Information
11.5.2 Geropharm Overview
11.5.3 Geropharm Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Geropharm Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Geropharm Recent Developments
11.6 Biocon
11.6.1 Biocon Company Information
11.6.2 Biocon Overview
11.6.3 Biocon Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Biocon Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Biocon Recent Developments
11.7 Wockhardt
11.7.1 Wockhardt Company Information
11.7.2 Wockhardt Overview
11.7.3 Wockhardt Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Wockhardt Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Wockhardt Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Biosimilar Insulin Glargine Industry Chain Analysis
12.2 Biosimilar Insulin Glargine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Biosimilar Insulin Glargine Production Mode & Process
12.4 Biosimilar Insulin Glargine Sales and Marketing
12.4.1 Biosimilar Insulin Glargine Sales Channels
12.4.2 Biosimilar Insulin Glargine Distributors
12.5 Biosimilar Insulin Glargine Customers
13 Market Dynamics
13.1 Biosimilar Insulin Glargine Industry Trends
13.2 Biosimilar Insulin Glargine Market Drivers
13.3 Biosimilar Insulin Glargine Market Challenges
13.4 Biosimilar Insulin Glargine Market Restraints
14 Key Findings in The Global Biosimilar Insulin Glargine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Biosimilar Insulin Glargine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Pre-filled
Table 3. Major Manufacturers of Cartridge
Table 4. Global Biosimilar Insulin Glargine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Biosimilar Insulin Glargine Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Biosimilar Insulin Glargine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Biosimilar Insulin Glargine Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2018-2024)
Table 9. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2024-2029)
Table 10. Global Biosimilar Insulin Glargine Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Biosimilar Insulin Glargine Sales by Region (2018-2024) & (K Units)
Table 12. Global Biosimilar Insulin Glargine Sales by Region (2024-2029) & (K Units)
Table 13. Global Biosimilar Insulin Glargine Sales Market Share by Region (2018-2024)
Table 14. Global Biosimilar Insulin Glargine Sales Market Share by Region (2024-2029)
Table 15. Global Biosimilar Insulin Glargine Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Biosimilar Insulin Glargine Sales Share by Manufacturers (2018-2024)
Table 17. Global Biosimilar Insulin Glargine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Biosimilar Insulin Glargine Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Biosimilar Insulin Glargine, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Biosimilar Insulin Glargine Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Biosimilar Insulin Glargine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Biosimilar Insulin Glargine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Insulin Glargine as of 2022)
Table 23. Global Key Manufacturers of Biosimilar Insulin Glargine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Biosimilar Insulin Glargine, Product Offered and Application
Table 25. Global Key Manufacturers of Biosimilar Insulin Glargine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Biosimilar Insulin Glargine Sales by Type (2018-2024) & (K Units)
Table 28. Global Biosimilar Insulin Glargine Sales by Type (2024-2029) & (K Units)
Table 29. Global Biosimilar Insulin Glargine Sales Share by Type (2018-2024)
Table 30. Global Biosimilar Insulin Glargine Sales Share by Type (2024-2029)
Table 31. Global Biosimilar Insulin Glargine Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Biosimilar Insulin Glargine Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Biosimilar Insulin Glargine Revenue Share by Type (2018-2024)
Table 34. Global Biosimilar Insulin Glargine Revenue Share by Type (2024-2029)
Table 35. Biosimilar Insulin Glargine Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Biosimilar Insulin Glargine Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global Biosimilar Insulin Glargine Sales by Application (2018-2024) & (K Units)
Table 38. Global Biosimilar Insulin Glargine Sales by Application (2024-2029) & (K Units)
Table 39. Global Biosimilar Insulin Glargine Sales Share by Application (2018-2024)
Table 40. Global Biosimilar Insulin Glargine Sales Share by Application (2024-2029)
Table 41. Global Biosimilar Insulin Glargine Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Biosimilar Insulin Glargine Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Biosimilar Insulin Glargine Revenue Share by Application (2018-2024)
Table 44. Global Biosimilar Insulin Glargine Revenue Share by Application (2024-2029)
Table 45. Biosimilar Insulin Glargine Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Biosimilar Insulin Glargine Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada Biosimilar Insulin Glargine Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Biosimilar Insulin Glargine Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Biosimilar Insulin Glargine Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Biosimilar Insulin Glargine Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Biosimilar Insulin Glargine Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Biosimilar Insulin Glargine Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Biosimilar Insulin Glargine Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Biosimilar Insulin Glargine Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Biosimilar Insulin Glargine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Biosimilar Insulin Glargine Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Biosimilar Insulin Glargine Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Biosimilar Insulin Glargine Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Biosimilar Insulin Glargine Sales by Country (2024-2029) & (K Units)
Table 60. Europe Biosimilar Insulin Glargine Sales by Type (2018-2024) & (K Units)
Table 61. Europe Biosimilar Insulin Glargine Sales by Type (2024-2029) & (K Units)
Table 62. Europe Biosimilar Insulin Glargine Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Biosimilar Insulin Glargine Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Biosimilar Insulin Glargine Sales by Application (2018-2024) & (K Units)
Table 65. Europe Biosimilar Insulin Glargine Sales by Application (2024-2029) & (K Units)
Table 66. Europe Biosimilar Insulin Glargine Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Biosimilar Insulin Glargine Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Biosimilar Insulin Glargine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Biosimilar Insulin Glargine Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Biosimilar Insulin Glargine Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Biosimilar Insulin Glargine Sales by Country (2018-2024) & (K Units)
Table 72. Europe Biosimilar Insulin Glargine Sales by Country (2024-2029) & (K Units)
Table 73. China Biosimilar Insulin Glargine Sales by Type (2018-2024) & (K Units)
Table 74. China Biosimilar Insulin Glargine Sales by Type (2024-2029) & (K Units)
Table 75. China Biosimilar Insulin Glargine Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Biosimilar Insulin Glargine Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Biosimilar Insulin Glargine Sales by Application (2018-2024) & (K Units)
Table 78. China Biosimilar Insulin Glargine Sales by Application (2024-2029) & (K Units)
Table 79. China Biosimilar Insulin Glargine Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Biosimilar Insulin Glargine Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Biosimilar Insulin Glargine Sales by Type (2018-2024) & (K Units)
Table 82. Asia Biosimilar Insulin Glargine Sales by Type (2024-2029) & (K Units)
Table 83. Asia Biosimilar Insulin Glargine Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Biosimilar Insulin Glargine Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Biosimilar Insulin Glargine Sales by Application (2018-2024) & (K Units)
Table 86. Asia Biosimilar Insulin Glargine Sales by Application (2024-2029) & (K Units)
Table 87. Asia Biosimilar Insulin Glargine Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Biosimilar Insulin Glargine Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Biosimilar Insulin Glargine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Biosimilar Insulin Glargine Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Biosimilar Insulin Glargine Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Biosimilar Insulin Glargine Sales by Region (2018-2024) & (K Units)
Table 93. Asia Biosimilar Insulin Glargine Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales by Country (2024-2029) & (K Units)
Table 107. Eli Lilly Company Information
Table 108. Eli Lilly Description and Major Businesses
Table 109. Eli Lilly Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Eli Lilly Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Eli Lilly Recent Developments
Table 112. Gan&Lee Company Information
Table 113. Gan&Lee Description and Major Businesses
Table 114. Gan&Lee Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Gan&Lee Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Gan&Lee Recent Developments
Table 117. Tonghua Dongbao Company Information
Table 118. Tonghua Dongbao Description and Major Businesses
Table 119. Tonghua Dongbao Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Tonghua Dongbao Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Tonghua Dongbao Recent Developments
Table 122. United Laboratory Company Information
Table 123. United Laboratory Description and Major Businesses
Table 124. United Laboratory Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. United Laboratory Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. United Laboratory Recent Developments
Table 127. Geropharm Company Information
Table 128. Geropharm Description and Major Businesses
Table 129. Geropharm Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Geropharm Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Geropharm Recent Developments
Table 132. Biocon Company Information
Table 133. Biocon Description and Major Businesses
Table 134. Biocon Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Biocon Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Biocon Recent Developments
Table 137. Wockhardt Company Information
Table 138. Wockhardt Description and Major Businesses
Table 139. Wockhardt Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Wockhardt Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Wockhardt Recent Developments
Table 142. Key Raw Materials Lists
Table 143. Raw Materials Key Suppliers Lists
Table 144. Biosimilar Insulin Glargine Distributors List
Table 145. Biosimilar Insulin Glargine Customers List
Table 146. Biosimilar Insulin Glargine Market Trends
Table 147. Biosimilar Insulin Glargine Market Drivers
Table 148. Biosimilar Insulin Glargine Market Challenges
Table 149. Biosimilar Insulin Glargine Market Restraints
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilar Insulin Glargine Product Picture
Figure 2. Global Biosimilar Insulin Glargine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Biosimilar Insulin Glargine Market Share by Type in 2022 & 2029
Figure 4. Pre-filled Product Picture
Figure 5. Cartridge Product Picture
Figure 6. Global Biosimilar Insulin Glargine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Biosimilar Insulin Glargine Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Retail Pharmacy
Figure 10. Others
Figure 11. Biosimilar Insulin Glargine Report Years Considered
Figure 12. Global Biosimilar Insulin Glargine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Biosimilar Insulin Glargine Revenue 2018-2029 (US$ Million)
Figure 14. Global Biosimilar Insulin Glargine Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 15. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2018-2029)
Figure 16. Global Biosimilar Insulin Glargine Sales 2018-2029 ((K Units)
Figure 17. Global Biosimilar Insulin Glargine Sales Market Share by Region (2018-2029)
Figure 18. US & Canada Biosimilar Insulin Glargine Sales YoY (2018-2029) & (K Units)
Figure 19. US & Canada Biosimilar Insulin Glargine Revenue YoY (2018-2029) & (US$ Million)
Figure 20. Europe Biosimilar Insulin Glargine Sales YoY (2018-2029) & (K Units)
Figure 21. Europe Biosimilar Insulin Glargine Revenue YoY (2018-2029) & (US$ Million)
Figure 22. China Biosimilar Insulin Glargine Sales YoY (2018-2029) & (K Units)
Figure 23. China Biosimilar Insulin Glargine Revenue YoY (2018-2029) & (US$ Million)
Figure 24. Asia (excluding China) Biosimilar Insulin Glargine Sales YoY (2018-2029) & (K Units)
Figure 25. Asia (excluding China) Biosimilar Insulin Glargine Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales YoY (2018-2029) & (K Units)
Figure 27. Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue YoY (2018-2029) & (US$ Million)
Figure 28. The Biosimilar Insulin Glargine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 29. The Top 5 and 10 Largest Manufacturers of Biosimilar Insulin Glargine in the World: Market Share by Biosimilar Insulin Glargine Revenue in 2022
Figure 30. Global Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Biosimilar Insulin Glargine Sales Market Share by Type (2018-2029)
Figure 32. Global Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2029)
Figure 33. Global Biosimilar Insulin Glargine Sales Market Share by Application (2018-2029)
Figure 34. Global Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2029)
Figure 35. US & Canada Biosimilar Insulin Glargine Sales Market Share by Type (2018-2029)
Figure 36. US & Canada Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2029)
Figure 37. US & Canada Biosimilar Insulin Glargine Sales Market Share by Application (2018-2029)
Figure 38. US & Canada Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2029)
Figure 39. US & Canada Biosimilar Insulin Glargine Revenue Share by Country (2018-2029)
Figure 40. US & Canada Biosimilar Insulin Glargine Sales Share by Country (2018-2029)
Figure 41. U.S. Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 42. Canada Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 43. Europe Biosimilar Insulin Glargine Sales Market Share by Type (2018-2029)
Figure 44. Europe Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2029)
Figure 45. Europe Biosimilar Insulin Glargine Sales Market Share by Application (2018-2029)
Figure 46. Europe Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2029)
Figure 47. Europe Biosimilar Insulin Glargine Revenue Share by Country (2018-2029)
Figure 48. Europe Biosimilar Insulin Glargine Sales Share by Country (2018-2029)
Figure 49. Germany Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 50. France Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 51. U.K. Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 52. Italy Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 53. Russia Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 54. China Biosimilar Insulin Glargine Sales Market Share by Type (2018-2029)
Figure 55. China Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2029)
Figure 56. China Biosimilar Insulin Glargine Sales Market Share by Application (2018-2029)
Figure 57. China Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2029)
Figure 58. Asia Biosimilar Insulin Glargine Sales Market Share by Type (2018-2029)
Figure 59. Asia Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2029)
Figure 60. Asia Biosimilar Insulin Glargine Sales Market Share by Application (2018-2029)
Figure 61. Asia Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2029)
Figure 62. Asia Biosimilar Insulin Glargine Revenue Share by Region (2018-2029)
Figure 63. Asia Biosimilar Insulin Glargine Sales Share by Region (2018-2029)
Figure 64. Japan Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 65. South Korea Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 66. China Taiwan Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 67. Southeast Asia Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 68. India Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 69. Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Biosimilar Insulin Glargine Revenue Share by Country (2018-2029)
Figure 74. Middle East, Africa and Latin America Biosimilar Insulin Glargine Sales Share by Country (2018-2029)
Figure 75. Brazil Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 76. Mexico Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 77. Turkey Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 78. Israel Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 79. GCC Countries Biosimilar Insulin Glargine Revenue (2018-2029) & (US$ Million)
Figure 80. Biosimilar Insulin Glargine Value Chain
Figure 81. Biosimilar Insulin Glargine Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries